한글목차

본 보고서는 주요 7개국(미국, EU 4개국(독일, 프랑스, 이탈리아, 스페인), 영국, 일본)의 수술 후 통증 치료제 LOTEMAX SM의 동향을 조사했으며, 치료제의 개요, 작용기전, 임상개발 데이터, 관련 법규, 시판 및 개발 중인 약품과의 경쟁 분석, 국가별 시장 규모 추정 및 예측, SWOT 분석, 애널리스트의 견해 등을 정리하여 전해드립니다.

보고서 주요 내용:

• 수술 후 통증의 시장 시나리오는 광범위한 연구와 의료비 지출 증가로 인해 향후 몇 년 동안 변화할 것으로 예상됩니다.
• 각 회사는 질병을 치료 및 개선하고, 과제를 평가하고, LOTEMAX SM의 우위에 영향을 미칠 수 있는 기회를 얻기 위해 새로운 접근 방식에 초점을 맞춘 치료제를 개발하고 있습니다.
• 다른 신흥 수술 후 통증 치료제가 LOTEMAX SM과 치열한 시장 경쟁을 벌일 것으로 예상되며, 가까운 시일 내에 후발주자 신흥 치료제가 출시되면 시장에 큰 영향을 미칠 것으로 전망됩니다.
• 법 규제 마일스톤과 개발 활동에 대한 자세한 설명을 통해 수술 후 통증에 대한 LOTEMAX SM의 현재 개발 시나리오를 제공합니다.
• 2024년부터 2032년까지 LOTEMAX SM의 예측 판매 데이터에 대한 상세한 분석을 통해 수술 후 통증에 대한 LOTEMAX SM의 전반적인 시나리오를 파악하여 치료제 포트폴리오에 대한 의사결정 과정에 도움을 줄 수 있습니다.

목차

제1장 보고서 소개

제2장 수술 후 통증의 LOTEMAX SM 개요

• 제품 상세
• 임상 개발
  • 임상 연구
  • 임상시험 정보
  • 안전성과 유효성
• 규제 마일스톤
• 기타 개발 활동
• 제품 프로파일

제3장 경쟁 구도(출시된 치료제)

제4장 경쟁 구도(후기 단계 신흥 치료제)

제5장 LOTEMAX SM : 시장 평가

• 수술 후 통증에 대한 LOTEMAX SM : 시장 전망
• 주요 7개국 분석
  • 수술 후 통증 치료제 LOTEMAX SM 시장 규모
• 국가별 시장 분석
  • 시장 규모 : 미국
  • 시장 규모 : 독일
  • 시장 규모 : 영국

제6장 SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight 소개

제12장 보고서 구입 옵션

영문목차

"LOTEMAX SM Market Size, Forecast, and Market Insight - 2032" report provides comprehensive insights about LOTEMAX SM for Postoperative pain in the seven major markets. A detailed picture of the LOTEMAX SM for Postoperative pain in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the LOTEMAX SM for Postoperative pain. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the LOTEMAX SM market forecast analysis for Postoperative pain in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in Postoperative pain.

Drug Summary:

LOTEMAX SM (loteprednol etabonate ophthalmic gel; 0.38%) is a corticosteroid indicated for treating postoperative inflammation and pain following ocular surgery; this is a new formulation of LOTEMAX. Compared to LOTEMAX Gel (0.5%), LOTEMAX SM delivers a submicron particle size for faster drug dissolution in tears. LOTEMAX SM provides two times greater penetration to the aqueous humor than LOTEMAX Gel. With its approval, physicians could prescribe patients the most advanced loteprednol etabonate formulation for treating postoperative inflammation and pain following ocular surgery.

Mechanism of action

Loteprednol etabonate is a corticosteroid. Corticosteroids have been shown to inhibit the inflammatory response to various inciting agents. They inhibit edema, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, fibroblast proliferation, deposition of collagen, and scar formation associated with inflammation. While glucocorticoids are known to bind to and activate the glucocorticoid receptor, the molecular mechanisms involved in glucocorticoid/glucocorticoid receptor-dependent modulation of inflammation are not established. However, corticosteroids are thought to inhibit prostaglandin production through several independent mechanisms.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the LOTEMAX SM description, mechanism of action, dosage and administration, research and development activities in Postoperative pain.
• Elaborated details on LOTEMAX SM regulatory milestones and other development activities have been provided in this report.
• The report also highlights the LOTEMAX SM research and development activities in Postoperative pain across the United States, Europe, and Japan.
• The report also covers the patents information with expiry timeline around LOTEMAX SM.
• The report contains forecasted sales of LOTEMAX SM for Postoperative pain till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Postoperative pain.
• The report also features the SWOT analysis with analyst views for LOTEMAX SM in Postoperative pain.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

LOTEMAX SM Analytical Perspective by DelveInsight

• In-depth LOTEMAX SM Market Assessment

This report provides a detailed market assessment of LOTEMAX SM for Postoperative pain in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

• LOTEMAX SM Clinical Assessment

The report provides the clinical trials information of LOTEMAX SM for Postoperative pain covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Postoperative pain is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence LOTEMAX SM dominance.
• Other emerging products for Postoperative pain are expected to give tough market competition to LOTEMAX SM and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of LOTEMAX SM in Postoperative pain.
• Our in-depth analysis of the forecasted sales data of LOTEMAX SM from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the LOTEMAX SM in Postoperative pain.

Key Questions:

• What is the product type, route of administration and mechanism of action of LOTEMAX SM?
• What is the clinical trial status of the study related to LOTEMAX SM in Postoperative pain and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the LOTEMAX SM development?
• What are the key designations that have been granted to LOTEMAX SM for Postoperative pain?
• What is the forecasted market scenario of LOTEMAX SM for Postoperative pain?
• What are the forecasted sales of LOTEMAX SM in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to LOTEMAX SM for Postoperative pain?
• Which are the late-stage emerging therapies under development for the treatment of Postoperative pain?

Table of Contents

1. Report Introduction

2. LOTEMAX SM Overview in Postoperative pain

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Regulatory Milestones
• 2.4. Other Developmental Activities
• 2.5. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. LOTEMAX SM Market Assessment

• 5.1. Market Outlook of LOTEMAX SM in Postoperative pain
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of LOTEMAX SM in the 7MM for Postoperative pain
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of LOTEMAX SM in the United States for Postoperative pain
  • 5.3.2. Market Size of LOTEMAX SM in Germany for Postoperative pain
  • 5.3.3. Market Size of LOTEMAX SM in France for Postoperative pain
  • 5.3.4. Market Size of LOTEMAX SM in Italy for Postoperative pain
  • 5.3.5. Market Size of LOTEMAX SM in Spain for Postoperative pain
  • 5.3.6. Market Size of LOTEMAX SM in the United Kingdom for Postoperative pain
  • 5.3.7. Market Size of LOTEMAX SM in Japan for Postoperative pain

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options